Trials / Terminated
TerminatedNCT05027867
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Kartos Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Conditions
- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer Extensive Stage
- Small Cell Lung Cancer Recurrent
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KRT-232 | Administered by mouth |
Timeline
- Start date
- 2021-12-06
- Primary completion
- 2022-08-26
- Completion
- 2022-08-26
- First posted
- 2021-08-30
- Last updated
- 2023-08-16
Locations
33 sites across 7 countries: United States, Australia, France, Germany, Hungary, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05027867. Inclusion in this directory is not an endorsement.